Benefits
Skin Hyperpigmentation Reduction
Hakozaki 2002 and subsequent trials showed niacinamide reduces hyperpigmentation, age spots, and melanin transfer in skin. Mechanism: inhibits melanosome transfer from melanocytes to keratinocytes.
Non-Melanoma Skin Cancer Risk Reduction (Chen 2015 ONTRAC Trial)
Landmark Chen 2015 ONTRAC trial: niacinamide 500 mg twice daily reduced non-melanoma skin cancer (basal cell + squamous cell) incidence by 23% in high-risk patients over 12 months. Mechanism: enhances DNA repair after UV damage; replenishes cellular ATP/NAD+ depleted by UV exposure.
Skin Barrier and Moisture
Niacinamide supports ceramide synthesis and skin barrier function. Improves transepidermal water loss and skin hydration.
Anti-Aging / Wrinkle Reduction
Multiple studies show niacinamide improves skin elasticity, fine lines, wrinkles. Beauty-from-within approach.
Acne Support
Niacinamide has anti-inflammatory effects relevant to acne; both oral and topical formulations show benefits.
Mechanism of action
NAD+ Precursor — Cellular Energy
Niacinamide is precursor to NAD+ (nicotinamide adenine dinucleotide) — coenzyme essential for hundreds of metabolic reactions; UV exposure depletes cellular NAD+; supplementation replenishes.
DNA Repair Enhancement
Niacinamide supports DNA repair mechanisms via PARP enzymes (which require NAD+). Foundation for skin cancer prevention effect.
Melanosome Transfer Inhibition
Niacinamide inhibits melanosome transfer from melanocytes to keratinocytes — reduces visible pigmentation. Mechanism for hyperpigmentation effects.
Anti-Inflammatory Effects
Niacinamide has documented anti-inflammatory effects on skin — relevant to acne, rosacea, and general skin inflammation.
Sebum Regulation
Niacinamide modulates sebum production — relevant to oily skin and acne applications.
Clinical trials
RCT of niacinamide 500 mg twice daily in 386 high-risk patients with prior non-melanoma skin cancer for 12 months.
386 high-risk patients with prior non-melanoma skin cancer history.
23% reduction in new non-melanoma skin cancer incidence (basal cell + squamous cell) vs placebo. Landmark trial establishing niacinamide for skin cancer prevention.
Trial of topical niacinamide for hyperpigmentation.
Adults with hyperpigmentation.
Significant reduction in hyperpigmentation; established melanosome transfer inhibition mechanism.
About this ingredient
DERMANIA is a SKIN HEALTH INGREDIENT developed by SAANROO (formerly Gencor Pacific) featuring NIACINAMIDE (NICOTINAMIDE / VITAMIN B3 amide form). NIACINAMIDE vs NIACIN: niacinamide is the AMIDE form of vitamin B3 — same nutritional B3 activity but DOES NOT cause niacin flush (the characteristic skin flushing from nicotinic acid); preferred for chronic supplementation due to no flushing and lower hepatotoxicity.
KEY DISTINCTIONS: (1) LANDMARK ONTRAC TRIAL (Chen 2015) established niacinamide for non-melanoma skin cancer prevention; (2) Multiple skin applications (hyperpigmentation, anti-aging, acne, barrier function); (3) NAD+ PRECURSOR mechanism.
EVIDENCE-BASED USES: (1) NON-MELANOMA SKIN CANCER PREVENTION (Chen 2015 ONTRAC, 23% risk reduction at 500 mg BID); (2) HYPERPIGMENTATION reduction (Hakozaki 2002); (3) Skin barrier and moisture; (4) Anti-aging / wrinkle reduction; (5) Acne support; (6) Sebum regulation.
CRITICAL CAUTIONS: (1) HIGH-DOSE HEPATOTOXICITY — at very high doses (>3 g/day) niacinamide can be hepatotoxic; typical supplemental doses (500-1000 mg/day) safe; verify product dosing; (2) NIACINAMIDE vs NIACIN — niacinamide does NOT cause flushing; do not confuse with niacin (nicotinic acid) for cardiovascular use; (3) FOR SKIN CANCER PREVENTION — Chen 2015 used 500 mg twice daily (1000 mg total) for high-risk patients; not for low-risk general population at this dose; consult dermatologist; (4) PREGNANCY/LACTATION — niacinamide safe at RDA-meeting doses; higher therapeutic doses for skin limited specific data; consult; (5) DOSE — Saanroo specifies recommended dose; for skin cancer prevention 500 mg BID per ONTRAC; for hyperpigmentation lower doses effective; (6) ORAL vs TOPICAL — niacinamide effective both orally and topically; oral provides systemic exposure relevant to skin cancer prevention; topical effective for hyperpigmentation; combined approach reasonable; (7) DURATION — skin effects build over 8-12 weeks; cancer prevention requires sustained use; (8) UV PROTECTION — niacinamide does NOT replace sunscreen; sun protection remains primary photoprotection; niacinamide complements; (9) DERMATOLOGIST CONSULTATION — for diagnosed skin conditions; especially for skin cancer history (ONTRAC was in patients with prior NMSC); (10) For COMPREHENSIVE SKIN HEALTH — sun protection, antioxidants, retinoids, gentle cleansing, hydration, niacinamide; integrative approach optimal; (11) Among the most evidence-based oral skin ingredients due to ONTRAC trial.